Welcome to the Oncomine Blog
Evaluating NGS technologies for in-house comprehensive genomic profiling
11/13/2024 |
Research
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic...
-
Biomarker Tests for Precision Oncology: DIY or Pay-for-Service?
Cancer patient management of is increasingly driven by biomarker assays – but how should we manage t... -
Evaluating the Oncomine Myeloid Assay GX for Detection of Key Variants
Dr. Yi Ding of Geisinger Medical Laboratories recently presented at the 2020 Association of Molecula... -
What is Comprehensive Genomic Profiling & is it the Right Solution for You?
What is comprehensive genomic profiling? Comprehensive genomic profiling, or CGP, is the simultaneou... -
The Importance of Detecting Copy Number Variants (CNVs) in the Cancer Genome
Structural variants in the cancer genome Gene amplification (copy number gain) and deletion (copy nu... -
Breakthrough Device Designation for Oncomine Dx Precision Test Provides Insights into Brain Tumors Fueled by a Common Genetic Mutation
Philip Scard knew immediately and intimately that the June 15 news release from Thermo Fisher Scient... -
The Impact of NGS in Hematology-Oncology
In aggressive forms of cancer such as acute myeloid leukemia (AML), accurate diagnosis is needed as ... -
The OncomineWorld Experience from Behind the Curtain
BACKGROUND: There is little to no point in saying that we are all living in an unprecedented time, b... -
Comprehensive Biomarker Testing Reveals RET Alteration to Change Course of NSCLC Patient’s Treatment Options and Survival Outcome
It’s been a tough road for Melissa Crouse, sometimes almost deadly. She had a lobe of her left lung ... -
Building a Case for In-House Next Generation Sequencing
Diagnostics lab team demonstrates how insourcing NGS makes sound financial sense and helps deliver c...